Anuradhika Kandula, MD
Endocrinology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kandula’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A85854 · Current
Licensed to practise in California · since 2004 · expires 2027-09-30 · Gulbarga University, Vijaynagara Institute of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$329,984
Medicare paid this office $329,984 for 642 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 69 | $126,913 | None |
| Return visit (30+ min) | 373 | $74,698 | $113 |
| New patient visit (60+ min) | 99 | $19,252 | $194 |
| Long return visit (40+ min) | 68 | $11,555 | $167 |
| Short return visit (20+ min) | 126 | $10,679 | $76 |
See all 13 services
| Injection, denosumab, 1 mg | 69 | $126,913 | None |
| Return visit (30+ min) | 373 | $74,698 | $113 |
| New patient visit (60+ min) | 99 | $19,252 | $194 |
| Long return visit (40+ min) | 68 | $11,555 | $167 |
| Short return visit (20+ min) | 126 | $10,679 | $76 |
| New patient visit (45+ min) | 67 | $8,798 | $131 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 340 | $6,170 | $15 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 67 | $4,603 | $30 |
| Ultrasound scan of head and neck soft tissue | 31 | $3,130 | $101 |
| Injection of drug or substance under skin or into muscle | 78 | $2,134 | $14 |
| Hemoglobin a1c level | 118 | $1,676 | $10 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 14 | $1,517 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,026 | $79 |
Who their Medicare patients are
642 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 11% · Women 71% · Also on Medicaid 14% · Health risk score 1.51. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 48% · Coronary heart disease 29% · Chronic kidney disease 29% · Cancer 21% · Atrial fibrillation 16% · Depression 16% · Heart failure 15% · COPD 13% · Dementia 8% · Stroke 8%.
The office billed $1,452,320, Medicare allowed $431,522 and paid $329,984; for 14,786 services of 25 kinds; $182,731 of it was for drugs given in the office and $147,253 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 642 | 14,786 | 74 | 1.51 | $1,452,320 | $329,984 |
| 2023 | 585 | 11,475 | 74 | 1.41 | $1,035,098 | $241,516 |
| 2022 | 556 | 10,981 | 74 | 1.44 | $891,534 | $214,886 |
| 2021 | 433 | 5,328 | 73 | 1.44 | $646,768 | $163,376 |
| 2020 | 377 | 3,534 | 74 | 1.48 | $489,218 | $111,984 |
| 2019 | 405 | 3,925 | 74 | 1.44 | $512,915 | $117,859 |
| 2018 | 365 | 5,745 | 73 | 1.34 | $437,534 | $103,251 |
| 2017 | 330 | 3,068 | 73 | 1.23 | $369,207 | $87,984 |
| 2016 | 258 | 1,582 | 73 | 1.28 | $255,871 | $64,779 |
| 2015 | 176 | 1,143 | 73 | 1.24 | $123,643 | $48,417 |
| 2014 | 158 | 1,127 | 72 | 1.38 | $117,823 | $45,630 |
| 2013 | 155 | 1,103 | 72 | 1.08 | $118,177 | $45,857 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Injection, denosumab, 1 mg | 52 | $86,676 | None |
| Return visit (30+ min) | 290 | $59,512 | $110 |
| Short return visit (20+ min) | 148 | $13,628 | $81 |
| New patient visit (60+ min) | 66 | $12,153 | $184 |
| New patient visit (45+ min) | 79 | $10,194 | $129 |
| Long return visit (40+ min) | 49 | $8,115 | $162 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 43 | $3,291 | $30 |
| Ultrasound scan of head and neck soft tissue | 29 | $2,992 | $103 |
| Telephone medical discussion with physician, 11-20 minutes | 43 | $2,949 | $63 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 14 | $1,766 | $126 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,761 | $80 |
| Influenza vaccine split virus, preservative free | 24 | $1,723 | $72 |
| Injection of drug or substance under skin or into muscle | 58 | $1,686 | $14 |
| New patient visit (30+ min) | 14 | $1,407 | $101 |
| Hemoglobin a1c level | 79 | $1,190 | $10 |
| Administration of influenza virus vaccine | 25 | $924 | $37 |
| Telephone medical discussion provided by nonphysician professional, 21-30 minutes | 11 | $326 | $30 |
2022: 19 services
| Injection, denosumab, 1 mg | 41 | $64,342 | None |
| Return visit (30+ min) | 267 | $49,617 | $110 |
| Short return visit (20+ min) | 151 | $13,292 | $73 |
| New patient visit (45+ min) | 82 | $11,605 | $142 |
| Long return visit (40+ min) | 53 | $9,282 | $169 |
| New patient visit (60+ min) | 34 | $6,904 | $203 |
| Telephone medical discussion with physician, 21-30 minutes | 49 | $6,125 | $107 |
| Telephone medical discussion with physician, 11-20 minutes | 45 | $3,651 | $64 |
| Ultrasound scan of head and neck soft tissue | 33 | $3,119 | $95 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $1,950 | $31 |
| New patient visit (30+ min) | 18 | $1,720 | $96 |
| Influenza vaccine split virus, preservative free | 25 | $1,714 | $69 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 14 | $1,613 | $115 |
| Injection of drug or substance under skin or into muscle | 46 | $1,556 | $14 |
| Administration of influenza virus vaccine | 26 | $968 | $37 |
| Hemoglobin a1c level | 68 | $908 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $814 | $68 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $672 | $45 |
| Injection, zoledronic acid, 1 mg | 12 | $345 | None |
2021: 17 services
| Injection, denosumab, 1 mg | 32 | $47,578 | None |
| Return visit (30+ min) | 219 | $47,015 | $113 |
| Short return visit (20+ min) | 121 | $11,761 | $81 |
| New patient visit (45+ min) | 64 | $9,952 | $156 |
| New patient visit (60+ min) | 37 | $7,687 | $208 |
| Long return visit (40+ min) | 28 | $5,163 | $167 |
| Ultrasound scan of head and neck soft tissue | 45 | $5,094 | $113 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | $4,533 | $111 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | $3,842 | $74 |
| New patient visit (30+ min) | 20 | $2,087 | $104 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 22 | $1,785 | $29 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 12 | $1,404 | $117 |
| Influenza vaccine split virus, preservative free | 13 | $848 | $65 |
| Injection of drug or substance under skin or into muscle | 34 | $749 | $12 |
| Hemoglobin a1c level | 39 | $524 | $10 |
| Administration of influenza virus vaccine | 15 | $329 | $22 |
| Blood glucose (sugar) test performed by hand-held instrument | 27 | $121 | $3 |
2020: 16 services
| Injection, denosumab, 1 mg | 25 | $37,354 | None |
| Return visit (30+ min) | 147 | $22,926 | $91 |
| Short return visit (20+ min) | 200 | $18,735 | $62 |
| New patient visit (45+ min) | 49 | $7,160 | $146 |
| Telephone medical discussion with physician, 11-20 minutes | 58 | $5,266 | $72 |
| Ultrasound scan of head and neck soft tissue | 37 | $3,873 | $105 |
| Long return visit (40+ min) | 21 | $2,995 | $136 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $2,408 | $100 |
| New patient visit (30+ min) | 21 | $2,081 | $99 |
| Telephone medical discussion with physician, 5-10 minutes | 38 | $2,059 | $44 |
| New patient visit (60+ min) | 11 | $2,021 | $184 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 13 | $1,044 | $34 |
| Hemoglobin a1c level | 80 | $803 | $10 |
| Injection of drug or substance under skin or into muscle | 25 | $516 | $13 |
| Blood glucose (sugar) test performed by hand-held instrument | 80 | $271 | $3 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 13 | $149 | $11 |
2019: 15 services
| Return visit (30+ min) | 179 | $29,853 | $96 |
| Injection, denosumab, 1 mg | 24 | $29,162 | None |
| Short return visit (20+ min) | 249 | $25,167 | $64 |
| New patient visit (45+ min) | 85 | $11,854 | $139 |
| Ultrasound scan of head and neck soft tissue | 52 | $5,390 | $104 |
| New patient visit (60+ min) | 20 | $3,333 | $167 |
| Hemoglobin a1c level | 140 | $3,092 | $11 |
| Long return visit (40+ min) | 17 | $2,096 | $123 |
| Influenza vaccine split virus, preservative free | 30 | $1,699 | $55 |
| New patient visit (30+ min) | 15 | $1,455 | $97 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 13 | $1,443 | $111 |
| Blood glucose (sugar) test performed by hand-held instrument | 143 | $980 | $3 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 11 | $853 | $32 |
| Administration of influenza virus vaccine | 34 | $718 | $21 |
| Injection of drug or substance under skin or into muscle | 26 | $567 | $16 |
2018: 12 services
| Injection, denosumab, 1 mg | 22 | $26,218 | None |
| Short return visit (20+ min) | 248 | $23,301 | $59 |
| Return visit (30+ min) | 144 | $21,596 | $91 |
| New patient visit (45+ min) | 78 | $11,270 | $144 |
| Ultrasound scan of head and neck soft tissue | 54 | $5,208 | $95 |
| New patient visit (60+ min) | 20 | $3,268 | $163 |
| Hemoglobin a1c level | 139 | $3,126 | $12 |
| Long return visit (40+ min) | 18 | $2,461 | $123 |
| Influenza vaccine split virus, preservative free | 24 | $1,251 | $52 |
| Blood glucose (sugar) test performed by hand-held instrument | 138 | $854 | $3 |
| Injection of drug or substance under skin or into muscle | 24 | $835 | $18 |
| Administration of influenza virus vaccine | 30 | $772 | $26 |
2017: 13 services
| Short return visit (20+ min) | 223 | $23,760 | $60 |
| Injection, denosumab, 1 mg | 14 | $15,852 | None |
| New patient visit (45+ min) | 102 | $13,718 | $134 |
| Return visit (30+ min) | 108 | $13,035 | $84 |
| New patient visit (60+ min) | 29 | $5,509 | $190 |
| Ultrasound scan of head and neck soft tissue | 45 | $4,727 | $105 |
| Fine needle aspiration using imaging guidance | 17 | $4,173 | $135 |
| Hemoglobin a1c level | 111 | $2,688 | $13 |
| Ultrasonic guidance for needle placement | 17 | $966 | $48 |
| Blood glucose (sugar) test performed by hand-held instrument | 113 | $687 | $3 |
| Injection of drug or substance under skin or into muscle | 17 | $620 | $24 |
| Influenza vaccine split virus, preservative free | 11 | $529 | $48 |
| Administration of influenza virus vaccine | 13 | $420 | $32 |
2016: 17 services
| Return visit (30+ min) | 136 | $20,638 | $91 |
| Short return visit (20+ min) | 145 | $14,222 | $63 |
| New patient visit (45+ min) | 60 | $8,369 | $139 |
| Ultrasound scan of head and neck soft tissue | 35 | $4,074 | $116 |
| Fine needle aspiration using imaging guidance | 16 | $3,146 | $126 |
| Hemoglobin a1c level | 98 | $2,373 | $13 |
| New patient visit (60+ min) | 13 | $2,187 | $168 |
| Long return visit (40+ min) | 13 | $1,748 | $134 |
| Ultrasonic guidance for needle placement | 18 | $1,088 | $49 |
| Blood test, thyroid stimulating hormone (tsh) | 41 | $1,077 | $22 |
| Blood glucose (sugar) level | 92 | $796 | $5 |
| Dxa bone density measurement of hip, pelvis, spine | 15 | $784 | $52 |
| Administration of influenza virus vaccine | 24 | $760 | $32 |
| Thyroxine (thyroid chemical), free | 41 | $577 | $12 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 17 | $306 | $18 |
| Insertion of needle into vein for collection of blood sample | 84 | $276 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 40 | $125 | $3 |
2015: 17 services
| Return visit (30+ min) | 97 | $16,348 | $91 |
| Short return visit (20+ min) | 92 | $8,646 | $62 |
| New patient visit (45+ min) | 35 | $5,061 | $145 |
| Ultrasound scan of head and neck soft tissue | 36 | $4,225 | $114 |
| New patient visit (60+ min) | 15 | $2,851 | $190 |
| Fine needle aspiration using imaging guidance | 11 | $2,039 | $136 |
| Hemoglobin a1c level | 72 | $1,802 | $13 |
| Blood test, thyroid stimulating hormone (tsh) | 47 | $1,123 | $22 |
| Dxa bone density measurement of hip, pelvis, spine | 15 | $786 | $52 |
| Ultrasonic guidance for needle placement | 11 | $757 | $58 |
| Blood glucose (sugar) level | 73 | $738 | $5 |
| Thyroxine (thyroid chemical), free | 47 | $603 | $12 |
| Insertion of needle into vein for collection of blood sample | 111 | $538 | $3 |
| Administration of influenza virus vaccine | 16 | $509 | $32 |
| Influenza vaccine, trivalent derived from cell cultures | 16 | $349 | $22 |
| Urine microalbumin (protein) level | 34 | $278 | $8 |
| Creatinine level to test for kidney function or muscle injury | 34 | $248 | $7 |
2014: 15 services
| Return visit (30+ min) | 87 | $14,771 | $88 |
| Short return visit (20+ min) | 95 | $9,781 | $64 |
| Ultrasound scan of head and neck soft tissue | 30 | $3,571 | $115 |
| New patient visit (45+ min) | 23 | $3,444 | $150 |
| New patient visit (60+ min) | 12 | $2,259 | $188 |
| Hemoglobin a1c level | 65 | $1,707 | $13 |
| Blood test, thyroid stimulating hormone (tsh) | 47 | $1,213 | $22 |
| Dxa bone density measurement of hip, pelvis, spine | 13 | $814 | $63 |
| Blood glucose (sugar) level | 69 | $733 | $5 |
| Administration of influenza virus vaccine | 24 | $716 | $30 |
| Thyroxine (thyroid chemical), free | 47 | $651 | $12 |
| Insertion of needle into vein for collection of blood sample | 102 | $541 | $3 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 25 | $362 | $14 |
| Urine microalbumin (protein) level | 26 | $217 | $7 |
| Creatinine level to test for kidney function or muscle injury | 26 | $195 | $7 |
2013: 15 services
| Return visit (30+ min) | 82 | $13,641 | $82 |
| Short return visit (20+ min) | 90 | $8,966 | $59 |
| New patient visit (45+ min) | 28 | $3,875 | $138 |
| Ultrasound scan of head and neck soft tissue | 31 | $3,669 | $118 |
| New patient visit (60+ min) | 20 | $3,471 | $174 |
| Hemoglobin a1c level | 64 | $1,600 | $13 |
| Blood test, thyroid stimulating hormone (tsh) | 49 | $1,273 | $23 |
| Dxa bone density measurement of hip, pelvis, spine | 16 | $981 | $61 |
| Blood glucose (sugar) level | 67 | $722 | $5 |
| Thyroxine (thyroid chemical), free | 49 | $696 | $12 |
| Administration of influenza virus vaccine | 21 | $675 | $32 |
| Insertion of needle into vein for collection of blood sample | 101 | $506 | $3 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 21 | $302 | $14 |
| Urine microalbumin (protein) level | 28 | $221 | $7 |
| Creatinine level to test for kidney function or muscle injury | 27 | $191 | $7 |
Drugs they prescribed that Part D paid
$1,820,785
Pharmacies billed $1,820,785 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,841) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,812 generic and 1,796 brand-name prescriptions · $1,820,785 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 206 | $334,645 | $1,624 |
| Jardiance | 156 | $192,514 | $1,234 |
| Januvia | 114 | $133,177 | $1,168 |
| Farxiga | 105 | $117,947 | $1,123 |
| Rybelsus | 64 | $109,887 | $1,717 |
See all 55 drugs
| Ozempic | 206 | $334,645 | $1,624 |
| Jardiance | 156 | $192,514 | $1,234 |
| Januvia | 114 | $133,177 | $1,168 |
| Farxiga | 105 | $117,947 | $1,123 |
| Rybelsus | 64 | $109,887 | $1,717 |
| Trulicity | 58 | $104,089 | $1,795 |
| Toujeo Max Solostar | 50 | $102,072 | $2,041 |
| Tradjenta | 85 | $89,465 | $1,053 |
| Tresiba Flextouch U-100 | 75 | $70,838 | $945 |
| Toujeo Solostar | 95 | $64,176 | $676 |
| Forteo | 13 | $53,614 | $4,124 |
| Tresiba Flextouch U-200 | 28 | $52,544 | $1,877 |
| Mounjaro | 34 | $41,816 | $1,230 |
| Humalog Kwikpen U-200 | 19 | $35,452 | $1,866 |
| Janumet | 26 | $24,229 | $932 |
| Humulin R U-500 Kwikpen | 12 | $22,587 | $1,882 |
| Janumet Xr | 15 | $17,115 | $1,141 |
| Humalog Kwikpen U-100 | 49 | $12,939 | $264 |
| Synthroid | 127 | $12,560 | $99 |
| Novolog Flexpen | 55 | $11,933 | $217 |
| Nano 2nd Gen Pen Needle | 93 | $10,166 | $109 |
| Fiasp Flextouch | 13 | $9,513 | $732 |
| Cinacalcet | 14 | $8,731 | $624 |
| Humalog | 16 | $7,310 | $457 |
| Nateglinide | 95 | $6,508 | $69 |
| Lantus Solostar | 29 | $4,979 | $172 |
| Levemir Flexpen | 16 | $4,219 | $264 |
| Levothyroxine | 348 | $4,117 | $12 |
| Testosterone | 23 | $3,681 | $160 |
| Ultra-Fine Mini Pen Needle | 34 | $3,627 | $107 |
| Novolog | 18 | $3,324 | $185 |
| Ultra-Fine Short Pen Needle | 26 | $3,321 | $128 |
| Insulin Lispro Kwikpen U-100 | 12 | $2,289 | $191 |
| Ultra-Fine Nano Pen Needle | 18 | $2,139 | $119 |
| Metformin | 234 | $1,960 | $8 |
| Hydrocortisone | 32 | $1,909 | $60 |
| Glipizide | 144 | $1,523 | $11 |
| Metformin Hcl Er | 182 | $1,471 | $8 |
| Droplet Pen Needle | 18 | $1,400 | $78 |
| Autoshield Duo Pen Needle | 15 | $1,398 | $93 |
| Pioglitazone | 108 | $1,236 | $11 |
| Rosuvastatin | 52 | $1,216 | $23 |
| Levoxyl | 20 | $1,182 | $59 |
| Ezetimibe | 30 | $1,005 | $34 |
| Atorvastatin | 128 | $889 | $7 |
| Methimazole | 53 | $812 | $15 |
| Alendronate | 74 | $780 | $11 |
| Losartan | 70 | $717 | $10 |
| Glimepiride | 37 | $715 | $19 |
| Pravastatin | 29 | $709 | $24 |
| Lisinopril | 24 | $375 | $16 |
| Simvastatin | 60 | $341 | $6 |
| Metoprolol | 12 | $101 | $8 |
| Dexamethasone | 30 | $73 | $2 |
| Potassium Chloride | 11 | $14 | $1 |
Year by year
| 2024 | 3,841 | 520 | 0% (0) | 47% | $1,820,785 |
| 2023 | 3,657 | 491 | 0% (0) | 50% | $1,993,596 |
| 2022 | 2,889 | 413 | 0% (0) | 52% | $1,551,287 |
| 2021 | 2,564 | 318 | 0% (0) | 52% | $1,327,338 |
| 2020 | 2,440 | 275 | 0% (0) | 51% | $1,102,433 |
| 2019 | 2,382 | 352 | 0% (0) | 49% | $954,218 |
| 2018 | 2,248 | 324 | 0% (0) | 50% | $802,297 |
| 2017 | 2,134 | 308 | 0% (0) | 49% | $647,948 |
| 2016 | 3,244 | 373 | 0% (0) | 51% | $902,980 |
| 2015 | 4,981 | 420 | 0% (0) | 49% | $1,247,740 |
| 2014 | 4,522 | 399 | None | 52% | $1,036,126 |
| 2013 | 3,896 | 333 | 0% (0) | 52% | $741,896 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 60 drugs
| Trulicity | 144 | $245,845 | $1,707 |
| Ozempic | 80 | $146,255 | $1,828 |
| Tradjenta | 113 | $123,087 | $1,089 |
| Jardiance | 128 | $121,817 | $952 |
| Januvia | 90 | $118,896 | $1,321 |
| Toujeo Solostar | 158 | $111,855 | $708 |
| Rybelsus | 71 | $111,167 | $1,566 |
| Farxiga | 109 | $96,811 | $888 |
| Toujeo Max Solostar | 51 | $90,269 | $1,770 |
| Novolog Flexpen | 76 | $83,133 | $1,094 |
| Tresiba Flextouch U-200 | 41 | $68,248 | $1,665 |
| Humalog Kwikpen U-100 | 63 | $64,335 | $1,021 |
| Forteo | 13 | $56,669 | $4,359 |
| Tresiba Flextouch U-100 | 58 | $55,697 | $960 |
| Humalog | 29 | $53,164 | $1,833 |
| Humalog Kwikpen U-200 | 19 | $39,945 | $2,102 |
| Bydureon Bcise | 15 | $32,571 | $2,171 |
| Janumet | 34 | $30,702 | $903 |
| Lantus Solostar | 33 | $26,349 | $798 |
| Lantus | 15 | $22,196 | $1,480 |
| Novolog | 35 | $19,549 | $559 |
| Janumet Xr | 19 | $16,504 | $869 |
| Synthroid | 112 | $12,393 | $111 |
| Vascepa | 17 | $11,701 | $688 |
| Levemir Flexpen | 13 | $10,784 | $830 |
| Nateglinide | 97 | $9,554 | $98 |
| Nano 2nd Gen Pen Needle | 85 | $8,187 | $96 |
| Cinacalcet | 13 | $7,383 | $568 |
| Levemir | 13 | $6,154 | $473 |
| Levothyroxine | 325 | $5,433 | $17 |
| Insulin Aspart Flexpen | 17 | $5,135 | $302 |
| Tirosint | 11 | $3,639 | $331 |
| Testosterone | 19 | $3,352 | $176 |
| Ultra-Fine Nano Pen Needle | 24 | $2,904 | $121 |
| Ultra-Fine Short Pen Needle | 17 | $2,399 | $141 |
| Hydrocortisone | 30 | $2,283 | $76 |
| Metformin | 196 | $2,224 | $11 |
| Pioglitazone | 88 | $2,198 | $25 |
| Glipizide | 134 | $1,985 | $15 |
| Metformin Hcl Er | 133 | $1,958 | $15 |
| Ezetimibe | 18 | $1,848 | $103 |
| Novolin N | 12 | $1,789 | $149 |
| Ultra-Fine Mini Pen Needle | 17 | $1,681 | $99 |
| Droplet Pen Needle | 24 | $1,410 | $59 |
| Atorvastatin | 110 | $1,322 | $12 |
| Alendronate | 72 | $1,316 | $18 |
| Rosuvastatin | 37 | $1,096 | $30 |
| Glimepiride | 49 | $895 | $18 |
| Simvastatin | 61 | $764 | $13 |
| Losartan | 41 | $492 | $12 |
| Methimazole | 60 | $481 | $8 |
| Pravastatin | 23 | $463 | $20 |
| Lisinopril | 23 | $344 | $15 |
| Prednisone | 13 | $265 | $20 |
| Testosterone Cypionate | 11 | $219 | $20 |
| Gabapentin | 15 | $213 | $14 |
| Potassium Chloride | 11 | $185 | $17 |
| Glipizide Er | 11 | $180 | $16 |
| Hydrochlorothiazide | 18 | $73 | $4 |
| Dexamethasone | 20 | $15 | $1 |
2022: 49 drugs
| Trulicity | 119 | $180,882 | $1,520 |
| Tradjenta | 115 | $122,428 | $1,065 |
| Januvia | 77 | $106,571 | $1,384 |
| Novolog Flexpen | 105 | $103,990 | $990 |
| Ozempic | 56 | $94,032 | $1,679 |
| Toujeo Solostar | 116 | $93,364 | $805 |
| Jardiance | 92 | $81,235 | $883 |
| Toujeo Max Solostar | 40 | $65,093 | $1,627 |
| Farxiga | 64 | $60,210 | $941 |
| Tresiba Flextouch U-100 | 68 | $56,408 | $830 |
| Tresiba Flextouch U-200 | 31 | $55,881 | $1,803 |
| Rybelsus | 39 | $53,367 | $1,368 |
| Humalog Kwikpen U-200 | 21 | $45,055 | $2,145 |
| Humalog Kwikpen U-100 | 58 | $40,871 | $705 |
| Lantus Solostar | 44 | $34,190 | $777 |
| Teriparatide | 11 | $29,114 | $2,647 |
| Janumet | 30 | $24,506 | $817 |
| Humalog | 11 | $23,221 | $2,111 |
| Victoza 3-Pak | 15 | $19,791 | $1,319 |
| Victoza 2-Pak | 18 | $19,029 | $1,057 |
| Cinacalcet | 15 | $18,663 | $1,244 |
| Bydureon Bcise | 17 | $15,685 | $923 |
| Kombiglyze Xr | 14 | $11,949 | $853 |
| Vascepa | 16 | $10,827 | $677 |
| Janumet Xr | 11 | $10,653 | $968 |
| Nano 2nd Gen Pen Needle | 118 | $10,336 | $88 |
| Levemir Flextouch | 12 | $10,273 | $856 |
| Nateglinide | 93 | $9,700 | $104 |
| Novolog | 21 | $9,279 | $442 |
| Synthroid | 44 | $5,268 | $120 |
| Levothyroxine | 272 | $4,752 | $17 |
| Ultra-Fine Nano Pen Needle | 22 | $3,486 | $158 |
| Tirosint | 11 | $2,411 | $219 |
| Ultra-Fine Mini Pen Needle | 26 | $2,286 | $88 |
| Metformin | 154 | $1,509 | $10 |
| Hydrocortisone | 19 | $1,387 | $73 |
| Glipizide | 111 | $1,297 | $12 |
| Metformin Hcl Er | 82 | $1,097 | $13 |
| Rosuvastatin | 36 | $1,054 | $29 |
| Atorvastatin | 72 | $1,010 | $14 |
| Pioglitazone | 42 | $863 | $21 |
| Droplet Pen Needle | 15 | $794 | $53 |
| Glimepiride | 50 | $761 | $15 |
| Alendronate | 49 | $703 | $14 |
| Methimazole | 45 | $500 | $11 |
| Losartan | 39 | $440 | $11 |
| Simvastatin | 43 | $256 | $6 |
| Lisinopril | 16 | $36 | $2 |
| Dexamethasone | 17 | $13 | $1 |
2021: 45 drugs
| Trulicity | 116 | $152,267 | $1,313 |
| Januvia | 94 | $101,379 | $1,078 |
| Toujeo Solostar | 128 | $100,681 | $787 |
| Tradjenta | 73 | $92,946 | $1,273 |
| Novolog Flexpen | 95 | $82,203 | $865 |
| Tresiba Flextouch U-200 | 36 | $72,590 | $2,016 |
| Jardiance | 94 | $70,923 | $755 |
| Ozempic | 39 | $64,260 | $1,648 |
| Tresiba Flextouch U-100 | 59 | $53,443 | $906 |
| Humalog Kwikpen U-100 | 57 | $52,224 | $916 |
| Forteo | 13 | $51,919 | $3,994 |
| Farxiga | 37 | $33,695 | $911 |
| Lantus Solostar | 56 | $29,304 | $523 |
| Toujeo Max Solostar | 17 | $29,028 | $1,708 |
| Victoza 2-Pak | 31 | $28,851 | $931 |
| Janumet | 33 | $27,092 | $821 |
| Tymlos | 11 | $24,791 | $2,254 |
| Humalog | 11 | $24,299 | $2,209 |
| Janumet Xr | 13 | $13,144 | $1,011 |
| Kombiglyze Xr | 17 | $12,873 | $757 |
| Nateglinide | 100 | $10,632 | $106 |
| Nano 2nd Gen Pen Needle | 125 | $10,306 | $82 |
| Vascepa | 13 | $8,454 | $650 |
| Levemir Flextouch | 12 | $7,844 | $654 |
| Levothyroxine | 216 | $4,826 | $22 |
| Ultra-Fine Nano Pen Needle | 43 | $4,308 | $100 |
| Novolog | 13 | $4,174 | $321 |
| Synthroid | 46 | $3,959 | $86 |
| Tirosint | 11 | $2,938 | $267 |
| Ultra-Fine Mini Pen Needle | 26 | $2,219 | $85 |
| Metformin | 155 | $1,290 | $8 |
| Potassium Chloride | 15 | $1,140 | $76 |
| Rosuvastatin | 30 | $1,008 | $34 |
| Glipizide | 88 | $926 | $11 |
| Glimepiride | 41 | $869 | $21 |
| Metformin Hcl Er | 46 | $848 | $18 |
| Pioglitazone | 37 | $706 | $19 |
| Atorvastatin | 62 | $520 | $8 |
| Losartan | 27 | $514 | $19 |
| Alendronate | 38 | $462 | $12 |
| Easy Touch Pen Needle | 13 | $391 | $30 |
| Methimazole | 46 | $352 | $8 |
| Simvastatin | 32 | $138 | $4 |
| Lisinopril | 23 | $36 | $2 |
| Dexamethasone | 13 | $12 | $1 |
2020: 41 drugs
| Trulicity | 102 | $113,809 | $1,116 |
| Januvia | 119 | $104,720 | $880 |
| Toujeo Solostar | 134 | $100,107 | $747 |
| Tradjenta | 91 | $87,698 | $964 |
| Novolog Flexpen | 69 | $74,455 | $1,079 |
| Forteo | 13 | $67,457 | $5,189 |
| Tresiba Flextouch U-200 | 42 | $64,078 | $1,526 |
| Tresiba Flextouch U-100 | 70 | $51,340 | $733 |
| Humalog Kwikpen U-100 | 58 | $51,297 | $884 |
| Jardiance | 72 | $47,124 | $655 |
| Lantus Solostar | 64 | $32,358 | $506 |
| Victoza 2-Pak | 36 | $26,787 | $744 |
| Janumet | 26 | $22,471 | $864 |
| Farxiga | 20 | $21,596 | $1,080 |
| Lantus | 13 | $19,112 | $1,470 |
| Toujeo Max Solostar | 12 | $13,518 | $1,127 |
| Nateglinide | 105 | $12,666 | $121 |
| Ultra-Fine Nano Pen Needle | 133 | $10,759 | $81 |
| Invokana | 14 | $9,582 | $684 |
| Kombiglyze Xr | 13 | $8,874 | $683 |
| Vascepa | 13 | $7,949 | $611 |
| Levothyroxine | 175 | $4,541 | $26 |
| Nano 2nd Gen Pen Needle | 49 | $3,712 | $76 |
| Novolog | 14 | $3,445 | $246 |
| Insulin Lispro Kwikpen U-100 | 11 | $3,128 | $284 |
| Synthroid | 29 | $2,438 | $84 |
| Ultra-Fine Mini Pen Needle | 19 | $1,804 | $95 |
| Rosuvastatin | 31 | $1,412 | $46 |
| Metformin | 152 | $1,398 | $9 |
| Glimepiride | 65 | $1,294 | $20 |
| Pioglitazone | 36 | $1,016 | $28 |
| Glipizide | 66 | $863 | $13 |
| Metformin Hcl Er | 48 | $858 | $18 |
| Ultra-Fine Short Pen Needle | 11 | $745 | $68 |
| Hydrocortisone | 20 | $669 | $33 |
| Atorvastatin | 61 | $594 | $10 |
| Methimazole | 54 | $476 | $9 |
| Alendronate | 43 | $449 | $10 |
| Losartan | 32 | $367 | $11 |
| Simvastatin | 32 | $147 | $5 |
| Lisinopril | 17 | $116 | $7 |
2019: 39 drugs
| Trulicity | 87 | $100,718 | $1,158 |
| Novolog Flexpen | 83 | $96,310 | $1,160 |
| Toujeo Solostar | 133 | $95,566 | $719 |
| Tradjenta | 98 | $75,246 | $768 |
| Humalog Kwikpen U-100 | 78 | $64,973 | $833 |
| Januvia | 62 | $64,048 | $1,033 |
| Tresiba Flextouch U-200 | 31 | $42,519 | $1,372 |
| Tresiba Flextouch U-100 | 55 | $40,988 | $745 |
| Lantus Solostar | 54 | $37,783 | $700 |
| Jardiance | 43 | $34,688 | $807 |
| Victoza 2-Pak | 37 | $26,957 | $729 |
| Janumet | 32 | $24,373 | $762 |
| Lantus | 25 | $23,755 | $950 |
| Farxiga | 13 | $16,100 | $1,238 |
| Levemir Flextouch | 25 | $15,281 | $611 |
| Nateglinide | 87 | $12,192 | $140 |
| Ultra-Fine Nano Pen Needle | 146 | $11,131 | $76 |
| Invokana | 14 | $9,544 | $682 |
| Kombiglyze Xr | 13 | $8,706 | $670 |
| Levothyroxine | 228 | $5,871 | $26 |
| Basaglar Kwikpen U-100 | 14 | $5,285 | $378 |
| Synthroid | 42 | $3,511 | $84 |
| Ultra-Fine Mini Pen Needle | 25 | $2,073 | $83 |
| Glimepiride | 83 | $1,663 | $20 |
| Metformin | 154 | $1,425 | $9 |
| Ultra-Fine Short Pen Needle | 20 | $1,347 | $67 |
| Rosuvastatin | 29 | $1,081 | $37 |
| Hydrocortisone | 26 | $1,067 | $41 |
| Metformin Hcl Er | 74 | $1,026 | $14 |
| Pioglitazone | 34 | $826 | $24 |
| Atorvastatin | 59 | $788 | $13 |
| Ultra-Fine Original Pen Needle | 13 | $625 | $48 |
| Alendronate | 59 | $617 | $10 |
| Methimazole | 46 | $504 | $11 |
| Glipizide | 31 | $386 | $12 |
| Glipizide Er | 11 | $268 | $24 |
| Losartan | 36 | $261 | $7 |
| Simvastatin | 32 | $232 | $7 |
| Lisinopril | 21 | $114 | $5 |
2018: 42 drugs
| Toujeo Solostar | 160 | $86,189 | $539 |
| Januvia | 71 | $67,856 | $956 |
| Novolog Flexpen | 69 | $63,743 | $924 |
| Humalog Kwikpen U-100 | 77 | $62,910 | $817 |
| Tradjenta | 100 | $62,625 | $626 |
| Trulicity | 58 | $52,996 | $914 |
| Lantus Solostar | 57 | $32,127 | $564 |
| Humalog | 19 | $29,613 | $1,559 |
| Lantus | 21 | $29,018 | $1,382 |
| Victoza 2-Pak | 36 | $25,078 | $697 |
| Tresiba Flextouch U-200 | 18 | $21,986 | $1,221 |
| Tresiba Flextouch U-100 | 34 | $21,549 | $634 |
| Sensipar | 20 | $20,686 | $1,034 |
| Farxiga | 24 | $19,596 | $816 |
| Jardiance | 20 | $18,657 | $933 |
| Janumet | 16 | $17,943 | $1,121 |
| Invokana | 20 | $14,289 | $714 |
| Levemir Flextouch | 25 | $11,291 | $452 |
| Kombiglyze Xr | 14 | $8,880 | $634 |
| Ultra-Fine Nano Pen Needle | 125 | $8,567 | $69 |
| Nateglinide | 60 | $8,008 | $133 |
| Levothyroxine | 222 | $5,231 | $24 |
| Basaglar Kwikpen U-100 | 11 | $3,650 | $332 |
| Synthroid | 43 | $2,423 | $56 |
| Ultra-Fine Mini Pen Needle | 32 | $2,040 | $64 |
| Glimepiride | 106 | $1,709 | $16 |
| Rosuvastatin | 32 | $1,569 | $49 |
| Metformin | 125 | $1,163 | $9 |
| Hydrocortisone | 13 | $887 | $68 |
| Metformin Hcl Er | 74 | $884 | $12 |
| Ultra-Fine Original Pen Needle | 16 | $808 | $51 |
| Atorvastatin | 46 | $716 | $16 |
| Pioglitazone | 35 | $599 | $17 |
| Alendronate | 46 | $491 | $11 |
| Glipizide | 28 | $466 | $17 |
| Pravastatin | 17 | $403 | $24 |
| Metoprolol | 12 | $378 | $31 |
| Methimazole | 33 | $371 | $11 |
| Enalapril Maleate | 13 | $287 | $22 |
| Losartan | 29 | $270 | $9 |
| Lisinopril | 21 | $180 | $9 |
| Simvastatin | 25 | $174 | $7 |
2017: 42 drugs
| Toujeo Solostar | 138 | $70,607 | $512 |
| Trulicity | 72 | $54,309 | $754 |
| Januvia | 68 | $52,232 | $768 |
| Humalog Kwikpen U-100 | 57 | $39,988 | $702 |
| Tradjenta | 63 | $39,011 | $619 |
| Novolog Flexpen | 48 | $38,455 | $801 |
| Lantus Solostar | 80 | $34,772 | $435 |
| Lantus | 28 | $27,760 | $991 |
| Invokana | 28 | $23,248 | $830 |
| Humalog | 23 | $22,219 | $966 |
| Sensipar | 20 | $20,820 | $1,041 |
| Jardiance | 28 | $17,435 | $623 |
| Janumet Xr | 14 | $16,148 | $1,153 |
| Levemir Flextouch | 31 | $15,968 | $515 |
| Janumet | 24 | $15,502 | $646 |
| Victoza 2-Pak | 25 | $15,010 | $600 |
| Farxiga | 19 | $14,501 | $763 |
| Tresiba Flextouch U-200 | 12 | $11,371 | $948 |
| Kombiglyze Xr | 17 | $7,781 | $458 |
| Nateglinide | 59 | $7,175 | $122 |
| Ultra-Fine Nano Pen Needle | 93 | $5,619 | $60 |
| Levothyroxine | 195 | $4,707 | $24 |
| Humalog Mix 75-25 | 11 | $4,419 | $402 |
| Synthroid | 40 | $2,271 | $57 |
| Metformin Hcl Er | 77 | $1,614 | $21 |
| Rosuvastatin | 36 | $1,504 | $42 |
| Metformin | 149 | $1,296 | $9 |
| Ultra-Fine Short Pen Needle | 13 | $1,286 | $99 |
| Glimepiride | 79 | $1,268 | $16 |
| Ultra-Fine Mini Pen Needle | 17 | $942 | $55 |
| Atorvastatin | 66 | $850 | $13 |
| Hydrocortisone | 13 | $805 | $62 |
| Bd Ultra-Fine Pen Needle | 11 | $692 | $63 |
| Pioglitazone | 39 | $630 | $16 |
| Methimazole | 53 | $515 | $10 |
| Pravastatin | 18 | $374 | $21 |
| Metoprolol | 12 | $320 | $27 |
| Glipizide | 18 | $305 | $17 |
| Lisinopril | 22 | $226 | $10 |
| Losartan | 35 | $186 | $5 |
| Simvastatin | 20 | $166 | $8 |
| Hydrochlorothiazide | 18 | $67 | $4 |
2016: 52 drugs
| Lantus Solostar | 201 | $107,060 | $533 |
| Januvia | 166 | $82,781 | $499 |
| Novolog Flexpen | 117 | $76,449 | $653 |
| Humalog Kwikpen U-100 | 84 | $74,719 | $890 |
| Tradjenta | 129 | $56,697 | $440 |
| Toujeo Solostar | 119 | $53,785 | $452 |
| Invokana | 87 | $39,829 | $458 |
| Levemir Flextouch | 63 | $32,952 | $523 |
| Lantus | 44 | $30,625 | $696 |
| Humalog | 38 | $26,283 | $692 |
| Janumet | 55 | $23,642 | $430 |
| Prolia | 23 | $22,648 | $985 |
| Farxiga | 35 | $21,367 | $610 |
| Crestor | 49 | $21,272 | $434 |
| Onglyza | 48 | $17,476 | $364 |
| Trulicity | 27 | $17,321 | $642 |
| Bydureon | 19 | $15,407 | $811 |
| Janumet Xr | 21 | $15,318 | $729 |
| Metformin Hcl Er | 51 | $15,159 | $297 |
| Tresiba Flextouch U-200 | 13 | $14,128 | $1,087 |
| Nateglinide | 147 | $13,357 | $91 |
| Victoza 2-Pak | 24 | $13,278 | $553 |
| Sensipar | 15 | $13,248 | $883 |
| Bd Ultra-Fine Pen Needle | 218 | $12,049 | $55 |
| Levemir | 12 | $7,816 | $651 |
| Kombiglyze Xr | 18 | $6,543 | $363 |
| Novolog | 12 | $6,111 | $509 |
| Levothyroxine | 208 | $3,874 | $19 |
| Benicar | 15 | $3,329 | $222 |
| Synthroid | 38 | $1,679 | $44 |
| Ulticare Pen Needle | 36 | $1,613 | $45 |
| Pioglitazone | 96 | $1,423 | $15 |
| Atorvastatin | 112 | $1,415 | $13 |
| Risedronate Sodium Dr | 12 | $1,366 | $114 |
| Metformin | 180 | $1,262 | $7 |
| Rosuvastatin | 14 | $1,007 | $72 |
| Methimazole | 99 | $955 | $10 |
| Glimepiride | 76 | $952 | $13 |
| Hydrocortisone | 21 | $939 | $45 |
| Enalapril Maleate | 32 | $684 | $21 |
| Unifine Pentips | 23 | $664 | $29 |
| Insulin | 20 | $500 | $25 |
| Easy Touch Pen Needle | 18 | $459 | $26 |
| Glipizide | 28 | $457 | $16 |
| Simvastatin | 24 | $285 | $12 |
| Lisinopril | 29 | $251 | $9 |
| Losartan | 47 | $225 | $5 |
| Alendronate | 36 | $204 | $6 |
| Pravastatin | 13 | $188 | $14 |
| Lovastatin | 15 | $140 | $9 |
| Amlodipine Besylate | 21 | $120 | $6 |
| Benazepril | 18 | $83 | $5 |
2015: 55 drugs
| Lantus Solostar | 368 | $187,223 | $509 |
| Novolog Flexpen | 195 | $123,578 | $634 |
| Januvia | 230 | $116,876 | $508 |
| Humalog Kwikpen U-100 | 170 | $106,112 | $624 |
| Tradjenta | 239 | $94,958 | $397 |
| Levemir Flextouch | 158 | $87,125 | $551 |
| Lantus | 101 | $62,608 | $620 |
| Prolia | 46 | $42,896 | $933 |
| Invokana | 79 | $33,828 | $428 |
| Crestor | 86 | $28,543 | $332 |
| Nateglinide | 249 | $25,091 | $101 |
| Novolog | 37 | $23,695 | $640 |
| Farxiga | 45 | $21,077 | $468 |
| Janumet | 50 | $20,891 | $418 |
| Onglyza | 53 | $20,700 | $391 |
| Bd Ultra-Fine Pen Needle | 399 | $19,909 | $50 |
| Victoza 2-Pak | 36 | $18,943 | $526 |
| Bydureon | 24 | $18,501 | $771 |
| Janumet Xr | 28 | $16,409 | $586 |
| Levemir | 21 | $15,938 | $759 |
| Humalog | 35 | $15,866 | $453 |
| Sensipar | 23 | $15,177 | $660 |
| Omega-3 Acid Ethyl Esters | 55 | $10,922 | $199 |
| Victoza 3-Pak | 14 | $9,057 | $647 |
| Vascepa | 33 | $7,715 | $234 |
| Levothyroxine | 317 | $5,616 | $18 |
| Byetta | 11 | $5,498 | $500 |
| Repaglinide | 27 | $4,898 | $181 |
| Novolog Mix 70-30 Flexpen | 12 | $4,876 | $406 |
| Metformin Hcl Er | 31 | $4,829 | $156 |
| Pioglitazone | 112 | $3,408 | $30 |
| Synthroid | 78 | $2,886 | $37 |
| Atorvastatin | 160 | $2,825 | $18 |
| Metformin | 258 | $1,736 | $7 |
| Ulticare | 39 | $1,652 | $42 |
| Amlodipine-Valsartan-Hctz | 13 | $1,578 | $121 |
| Hydrocortisone | 36 | $1,542 | $43 |
| Easy Touch Pen Needle | 43 | $1,193 | $28 |
| Alendronate | 147 | $1,140 | $8 |
| Methimazole | 138 | $1,134 | $8 |
| Sure Comfort | 32 | $1,004 | $31 |
| Glimepiride | 83 | $947 | $11 |
| Unifine Pentips | 27 | $788 | $29 |
| Insulin | 23 | $554 | $24 |
| Simvastatin | 77 | $534 | $7 |
| Insulin | 23 | $533 | $23 |
| Fenofibrate | 12 | $530 | $44 |
| Pravastatin | 24 | $480 | $20 |
| Losartan | 62 | $479 | $8 |
| Enalapril Maleate | 21 | $476 | $23 |
| Glipizide | 56 | $439 | $8 |
| Amlodipine Besylate | 28 | $140 | $5 |
| Losartan-Hydrochlorothiazide | 18 | $130 | $7 |
| Lisinopril | 25 | $121 | $5 |
| Benazepril | 16 | $90 | $6 |
2014: 60 drugs
| Lantus Solostar | 388 | $158,189 | $408 |
| Humalog | 224 | $110,599 | $494 |
| Novolog Flexpen | 209 | $106,334 | $509 |
| Januvia | 207 | $96,036 | $464 |
| Tradjenta | 218 | $80,097 | $367 |
| Levemir Flexpen | 121 | $52,864 | $437 |
| Lantus | 77 | $38,232 | $497 |
| Prolia | 34 | $29,648 | $872 |
| Crestor | 88 | $29,303 | $333 |
| Nateglinide | 179 | $21,410 | $120 |
| Bd Ultra-Fine Pen Needle | 428 | $20,810 | $49 |
| Janumet | 49 | $18,429 | $376 |
| Invokana | 43 | $16,380 | $381 |
| Onglyza | 41 | $16,173 | $394 |
| Bydureon | 34 | $16,141 | $475 |
| Levemir | 20 | $15,318 | $766 |
| Levemir Flextouch | 19 | $14,987 | $789 |
| Lovaza | 51 | $14,921 | $293 |
| Farxiga | 32 | $13,182 | $412 |
| Byetta | 30 | $12,760 | $425 |
| Novolog | 24 | $10,550 | $440 |
| Sensipar | 12 | $10,425 | $869 |
| Janumet Xr | 26 | $10,075 | $388 |
| Repaglinide | 15 | $8,279 | $552 |
| Victoza 2-Pak | 20 | $7,783 | $389 |
| Glumetza | 13 | $6,386 | $491 |
| Humulin R | 11 | $5,426 | $493 |
| Vascepa | 24 | $4,872 | $203 |
| Pioglitazone | 65 | $4,761 | $73 |
| Levothyroxine | 194 | $3,760 | $19 |
| Atelvia | 20 | $3,260 | $163 |
| Omega-3 Acid Ethyl Esters | 14 | $2,912 | $208 |
| Atorvastatin | 131 | $2,499 | $19 |
| Exforge Hct | 11 | $1,911 | $174 |
| Synthroid | 46 | $1,714 | $37 |
| Metformin | 220 | $1,543 | $7 |
| Hydrocortisone | 31 | $1,429 | $46 |
| Alendronate | 151 | $1,239 | $8 |
| Glimepiride | 96 | $1,150 | $12 |
| Fenofibrate | 19 | $1,092 | $57 |
| Insulin | 30 | $1,045 | $35 |
| Sure Comfort | 26 | $830 | $32 |
| Pravastatin | 37 | $805 | $22 |
| Easy Touch Pen Needle | 27 | $774 | $29 |
| Ulticare | 19 | $765 | $40 |
| Calcitonin-Salmon | 12 | $763 | $64 |
| Losartan | 65 | $711 | $11 |
| Methimazole | 63 | $668 | $11 |
| Unifine Pentips | 23 | $640 | $28 |
| Simvastatin | 85 | $543 | $6 |
| Glipizide | 46 | $474 | $10 |
| Insulin | 22 | $473 | $22 |
| Metoprolol | 11 | $352 | $32 |
| Metformin Hcl Er | 30 | $281 | $9 |
| Losartan-Hydrochlorothiazide | 24 | $219 | $9 |
| Gabapentin | 18 | $216 | $12 |
| Amlodipine Besylate | 36 | $197 | $5 |
| Metoprolol | 15 | $53 | $4 |
| Furosemide | 11 | $53 | $5 |
| Dexamethasone | 14 | $38 | $3 |
2013: 57 drugs
| Lantus Solostar | 340 | $103,500 | $304 |
| Januvia | 221 | $87,805 | $397 |
| Novolog Flexpen | 221 | $85,379 | $386 |
| Humalog | 130 | $65,238 | $502 |
| Levemir Flexpen | 120 | $42,050 | $350 |
| Tradjenta | 120 | $35,869 | $299 |
| Crestor | 91 | $24,457 | $269 |
| Lantus | 71 | $21,958 | $309 |
| Nateglinide | 157 | $19,330 | $123 |
| Bd Ultra-Fine Pen Needle | 416 | $19,074 | $46 |
| Lovaza | 65 | $17,772 | $273 |
| Sensipar | 18 | $16,389 | $910 |
| Prandin | 23 | $16,266 | $707 |
| Onglyza | 56 | $16,254 | $290 |
| Prolia | 19 | $15,967 | $840 |
| Janumet | 36 | $11,985 | $333 |
| Levemir | 20 | $10,211 | $511 |
| Bydureon | 24 | $9,065 | $378 |
| Pioglitazone | 67 | $7,809 | $117 |
| Repaglinide | 11 | $7,199 | $654 |
| Byetta | 19 | $6,667 | $351 |
| Glumetza | 13 | $6,551 | $504 |
| Kombiglyze Xr | 15 | $5,896 | $393 |
| Symlinpen 120 | 11 | $5,606 | $510 |
| Novolog | 19 | $5,218 | $275 |
| Diovan | 24 | $4,907 | $204 |
| Janumet Xr | 13 | $3,815 | $293 |
| Glucagon Emergency Kit | 13 | $3,418 | $263 |
| Atorvastatin | 89 | $2,902 | $33 |
| Atelvia | 18 | $2,547 | $142 |
| Levothyroxine | 215 | $2,480 | $12 |
| Novofine 32 | 23 | $2,119 | $92 |
| Fenofibrate | 43 | $2,094 | $49 |
| Exforge Hct | 13 | $1,864 | $143 |
| Benicar | 12 | $1,367 | $114 |
| Metformin Hcl Er | 42 | $1,307 | $31 |
| Ulticare | 44 | $1,252 | $28 |
| Synthroid | 21 | $1,111 | $53 |
| Metformin | 127 | $1,045 | $8 |
| Glipizide | 78 | $1,019 | $13 |
| Losartan | 74 | $1,012 | $14 |
| Hydrocortisone | 23 | $922 | $40 |
| Alendronate | 90 | $907 | $10 |
| Insulin | 27 | $875 | $32 |
| Simvastatin | 76 | $672 | $9 |
| Tirosint | 13 | $623 | $48 |
| Insulin | 20 | $494 | $25 |
| Methimazole | 51 | $453 | $9 |
| Amlodipine Besylate | 29 | $441 | $15 |
| Glimepiride | 44 | $437 | $10 |
| Pravastatin | 27 | $358 | $13 |
| Glyburide | 11 | $266 | $24 |
| Gabapentin | 15 | $239 | $16 |
| Losartan-Hydrochlorothiazide | 11 | $157 | $14 |
| Benazepril | 13 | $136 | $10 |
| Lisinopril | 14 | $89 | $6 |
| Enalapril Maleate | 14 | $75 | $5 |
Money from drug and device companies
$17 in 2025
| 2025 | 1 | 1 | None | $17 |
| 2024 | 2 | 3 | None | $192 |
| 2023 | 2 | 3 | None | $160 |
| 2022 | 1 | 3 | None | $97 |
| 2021 | 1 | 1 | None | $19 |
| 2019 | 3 | 6 | None | $101 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Freestyle Libre 3 | $17 | 1 payment
|
See the published payment
| Abbott Laboratories | Meals · 2025-02-10 | Freestyle Libre 3 | $17 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $192
| Beta Bionics | Ilet Bionic Pancreas | $164 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $28 | 2 payments
|
2023: $160
| Sanofi-Aventis U.S. | Toujeo | $146 | 2 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $14 | 1 payment
|
2022: $97
| Novo Nordisk | None | $97 | 3 payments
|
2021: $19
| AbbVie | Vraylar | $19 | 1 payment
|
2019: $101
| Novo Nordisk | Ozempic | $43 | 2 payments
|
| Medtronic MiniMed | Minimed 670g System | $38 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $20 | 1 payment
|
Professional record
- NPI
- 1164554051
- Licence
- CA A85854California A85854: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 50 E Hamilton Ave Ste 280, Campbell, CA, 95008
- NPI first listed
- 2007-03-09
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2690 S White Rd Ste 50, San Jose, CA, 95148